Pentoxifylline for Vascular Calcification in Kidney Disease

Exploring the Potential Effect of Pentoxifylline in Mitigating Vascular Calcification in Chronic Kidney Disease Patients

This study is research to find out if the drug pentoxifylline can help prevent or lessen the problem of blood vessel hardening (vascular calcification) in people with chronic kidney disease (CKD). People with CKD are at higher risk for heart problems and blood vessel hardening. Vascular calcification happens when calcium builds up in the blood vessels, making them stiff. Pentoxifylline is a drug that might have helpful effects that could reduce this hardening. In this study, some CKD patients will receive pentoxifylline in addition to their usual medications, while others will only receive their usual medications. The researchers will then compare the amount of vascular calcification in both groups over 6 months to see if pentoxifylline makes a difference. The goal is to learn if pentoxifylline could be a new way to protect the blood vessels of people with chronic kidney disease.

Inclusion Criteria:

• Estimated Glomerular Filtration Rate (eGFR) less than 60 ml/min/1.73 m² and greater than or equal to 15 ml/min/1.73 m².
• Adult patients, age 18 years or older.
• Diagnosis of Chronic Kidney Disease (CKD).
• Willing and able to provide informed consent.

Exclusion Criteria:

• Patients currently undergoing regular hemodialysis.
• History of kidney transplantation or are kidney transplant recipients.
• Pregnant females.
• Patients with a history of coronary artery bypass grafting (CABG).
• Known allergy or contraindication to pentoxifylline.
• Inability to comply with study procedures or attend follow-up visits.